Levodopa News and Research

RSS

Impax resubmits NDA for RYTARY providing updated safety and stability information

Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), announced today the resubmission of Impax's New Drug Application (NDA) for RYTARY (IPX066) to the U.S. Food and Drug Administration (FDA).

11 Apr 2014

New discovery opens door to development of new treatments that stop progression of Parkinson's disease

A research led by the Research Institute Vall d'Hebron (VHIR), in which the University of Valencia participated, has shown that pathological forms of the α-synuclein protein present in deceased patients with Parkinson's disease are able to initiate and spread in mice and primates the neurodegenerative process that typifies this disease.

10 Apr 2014

Parkinson disease patients with higher CSF experience faster cognitive decline

Counterintuitive Findings Offer New Insights into Parkinson Disease Pathology, According to New Research Published in The American Journal of Pathology

12 Mar 2014

NeuroDerm enrolls patients in second ND0612 Phase II clinical trial for treatment of Parkinson's disease

NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formulation under development for continuous subcutaneous administration through a patch pump. It is designed to provide steady levodopa blood levels for the treatment of Parkinson's disease.

11 Mar 2014

Circadian dysfunction blamed for sleepiness in PD patients

Patients with Parkinson’s disease, particularly those with excessive daytime sleepiness, have reduced melatonin levels and amplitude of the melatonin circadian rhythm, research shows.

6 Mar 2014

Deep-brain stimulation boosts PD patients’ driving performance

Deep-brain stimulation reduces errors among patients with Parkinson’s disease undergoing a driving simulator test, a study shows.

14 Jan 2014

Slower decline for patients with PARKIN-associated PD

Cognitive and motor decline may be slower in patients with early-onset Parkinson’s disease if they have PARKIN mutations, suggests an analysis of the Consortium on Risk for Early-Onset PD study.

8 Jan 2014

Deep brain stimulation may have beneficial effect on driving ability for Parkinson's disease patients

Deep brain stimulation may have a beneficial effect on driving ability for people with Parkinson's disease, according to a new study published in the December 18, 2013, online issue of Neurology®, the medical journal of the American Academy of Neurology. Deep brain stimulation uses a surgical implant similar to a pacemaker to send electrical impulses to the brain.

19 Dec 2013

Nonmotor symptoms may underlie Parkinson’s sleep complaints

In people with Parkinson’s disease, symptoms and comorbidities associated with insomnia differ from those associated with daytime sleepiness, US researchers report.

25 Nov 2013

Study: Depression in Parkinson's patients may reflect impaired striatal dopamine function

According to the Parkinson's Disease Foundation, up to 60% of individuals with Parkinson's disease (PD) exhibit mild to moderate depression, which is often underdiagnosed.

11 Oct 2013

Depression in Parkinson's disease people associated with reduced dopamine synthesis capacity

According to the Parkinson's Disease Foundation, up to 60% of individuals with Parkinson's disease exhibit mild to moderate depression, which is often underdiagnosed. It is unclear whether depression results from having a debilitating disease or reflects a parallel abnormal change in the brain caused by PD pathophysiology.

11 Oct 2013

Adamas Pharmaceuticals reports positive results from ADS-5102 Phase 2/3 EASED clinical trial

Adamas Pharmaceuticals, Inc. presented positive results today from the Phase 2/3 EASED clinical trial of ADS-5102 at the World Parkinson's Congress. ADS-5102 is Adamas' proprietary long-acting capsule formulation of amantadine HCl in development for the treatment of levodopa-induced dyskinesia in Parkinson's disease patients.

2 Oct 2013

Nonmotor symptoms contribute to early Parkinson’s subtypes

Researchers have characterized four distinct subgroups of patients with early Parkinson’s disease, distinguished by both motor and nonmotor symptoms.

18 Sep 2013

Mylan, Orion sign settlement, license agreement for generic version of STALEVO

Mylan Inc. today confirmed that Mylan Pharmaceuticals Inc. and Orion Corporation have entered into a settlement and license agreement settling the parties litigation in connection with Mylan's filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Carbidopa/Levodopa/Entacapone Tablets, 12.5 mg/50 mg/200 mg, 18.75 mg/75 mg/200 mg, 25 mg/100 mg/200 mg, 31.25 mg/125 mg/200 mg, 37.5 mg/150 mg/200 mg, and 50 mg/200 mg/200 mg.

25 Jul 2013

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.

19 Jun 2013

Vercise DBS System shows improvement in motor scores for patients with Parkinson's disease

Patients with Parkinson's disease using the Boston Scientific Corporation Vercise DBS (deep brain stimulation) System showed a significant improvement in motor scores according to interim data from the VANTAGE DBS study.

18 Jun 2013

Scientists find that mice develop age-related progressive motor symptoms of Parkinson's disease

The presence of Lewy bodies in nerve cells, formed by intracellular deposits of the protein α-synuclein, is a characteristic pathologic feature of Parkinson's Disease (PD). In the quest for an animal model of PD that mimics motor and non-motor symptoms of human PD, scientists have developed strains of mice that overexpress α-synuclein.

10 Jun 2013

NeuroDerm receives MJFF grant to develop ND0612 for treatment of Parkinson's disease

NeuroDerm, Ltd. was informed today that it was awarded, for the second time, a grant of $1M by The Michael J. Fox Foundation for Parkinson's Research to support the clinical development of its subcutaneously delivered drug for the treatment of Parkinson's disease.

3 Jun 2013

Merck updates on preladenant clinical program for treatment of Parkinson's disease

Merck, known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Merck's investigational adenosine A2A receptor antagonist for the treatment of Parkinson's disease.

24 May 2013

Civitas Therapeutics reports positive results from Phase 2 study of CVT-301 for Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, today announced positive topline results from a Phase 2 clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa).

20 Apr 2013